We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
As with all medicines, we will continue to closely monitor the safety and effectiveness of linerixibat as it is used more widely.
The MHRA has limited the use of nasal decongestant sprays containing xylometazoline and oxymetazoline to a maximum of five days due to side effects of prolonged use.
The Medicines and Healthcare products Regulatory Agency (MHRA) is pleased to announce the appointment of Jason Bonander as its new Chief Digital and Technology Officer (CDTO).
An MHRA-led investigation has exposed a £1.8 million illegal medicines and steroids network, leading to seven men being sentenced.
The MHRA has advised healthcare professionals to stop supplying the affected batch of Sertraline 100mg and return all remaining stock to their suppliers.
The MHRA continues to speed up access to medicines for patients, increase efficiency of regulation and help to attract innovation and investment in the UK’s thriving £100 billion life sciences industry.
Patients in the UK to get access to new treatments faster and still safely under new clinical trial regulations coming into force on 28 April 2026.
Specific batches of Napralief 250mg Gastro‑Resistant Tablets are being recalled because important safety and dosage information is missing from both the patient information leaflet and the outer carton.
As with any medicine, the MHRA will keep the safety and effectiveness of Enflonsia under close review.
The MHRA has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers.
NHS patients get faster access to groundbreaking treatments as government drives forward its 150-day clinical trial target.
By Dame Jennifer Dixon
As with any medicine, the MHRA will keep the safety and effectiveness of Wegovy under close review.
MHRA and eBay partnership removes 215 listings of potentially dangerous medicines from the eBay platform highlighting the benefits of private/public working.
New Access Work-Sharing Pathway for Priority Procedures.
MHRA approves olezarsen (Tryngolza) for the treatment of familial chylomicronemia syndrome
The MHRA continues to be at the forefront of innovation and secures multi-year funding to expand its pioneering AI Airlock programme.
The Medicines and Healthcare products Regulatory Agency and the US Food and Drug Administration are strengthening cooperation on medical device regulation, to support faster access to safe, innovative technologies for patien…
New partnership accelerates NHS patients' access to new medicines and will see UK benefit from greater life sciences industry investment.
As with any medicine, the MHRA will keep the safety and effectiveness of sevabertinib under close review.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).